Nov 15, 2022 / 10:20AM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst
We'll start a little early if we can. Is that okay? All right. Well, good morning, everyone. My name is Akash Tewari. I'm one of the therapeutics analyst here at Jefferies. It's a pleasure seeing you all. It's great to see this conference back to kind of full strength. I have the pleasure today of hosting Jazz Pharmaceuticals. Joining us today will be Renee Gala, CFO; Dan Swisher, President; Kelvin Tan, Chief Medical Officer; and then Samantha Pearce, Senior Vice President of Europe and International. So we'll have some good European Epidiolex questions.
So this is obviously -- next year is going to be a really big transition year for Jazz. We're going to start seeing generic entry, but at the same time, we're going to see growth on idiopathic hypersomnia for Xywav. We're going to see how Epidiolex really starts to play out. And I think it definitely looks like a -- what we would call a [garpy] name that has EPS and revenue expansion over the next few years. And I think if you can really grow, hit your Vision 2025, then I think a lot
Jazz Pharmaceuticals PLC at Jefferies London Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers